Do analysts rate APVO or PLUR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aptevo Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33 Pluri 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is APVO or PLUR more profitable?

Aptevo Therapeutics has a net margin of 0.00% compared to Pluri's net margin of -2,162.08%. Pluri's return on equity of 0.00% beat Aptevo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aptevo Therapeutics N/A -201.49% -119.21% Pluri -2,162.08% N/A -106.59%

Does the media prefer APVO or PLUR?

In the previous week, Pluri had 2 more articles in the media than Aptevo Therapeutics. MarketBeat recorded 4 mentions for Pluri and 2 mentions for Aptevo Therapeutics. Aptevo Therapeutics' average media sentiment score of 0.93 beat Pluri's score of 0.81 indicating that Aptevo Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aptevo Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pluri 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer APVO or KTTA?

Pasithea Therapeutics has a consensus target price of $3.00, suggesting a potential upside of 436.67%. Given Pasithea Therapeutics' higher probable upside, analysts plainly believe Pasithea Therapeutics is more favorable than Aptevo Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aptevo Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33 Pasithea Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger valuation and earnings, APVO or KTTA?

Pasithea Therapeutics is trading at a lower price-to-earnings ratio than Aptevo Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aptevo Therapeutics N/A N/A -$25.97M -$51.83 N/A Pasithea Therapeutics N/A N/A -$20.43M -$1.58 N/A

Is APVO or KTTA more profitable?

Pasithea Therapeutics' return on equity of -49.49% beat Aptevo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aptevo Therapeutics N/A -201.49% -119.21% Pasithea Therapeutics N/A -49.49% -46.81%

Do analysts rate APVO or NCEL?

NLS Pharmaceutics has a consensus target price of $23.00, suggesting a potential upside of 578.47%. Given NLS Pharmaceutics' higher probable upside, analysts clearly believe NLS Pharmaceutics is more favorable than Aptevo Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aptevo Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33 NLS Pharmaceutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable valuation and earnings, APVO or NCEL?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aptevo Therapeutics N/A N/A -$25.97M -$51.83 N/A NLS Pharmaceutics N/A N/A -$8.30M N/A N/A

Is APVO or NCEL more profitable?

NLS Pharmaceutics' return on equity of 0.00% beat Aptevo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aptevo Therapeutics N/A -201.49% -119.21% NLS Pharmaceutics N/A N/A N/A

Does the media refer more to APVO or NCEL?

In the previous week, Aptevo Therapeutics and Aptevo Therapeutics both had 2 articles in the media. NLS Pharmaceutics' average media sentiment score of 0.94 beat Aptevo Therapeutics' score of 0.93 indicating that NLS Pharmaceutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aptevo Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NLS Pharmaceutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate APVO or TPST?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aptevo Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33 Tempest Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has better earnings and valuation, APVO or TPST?

Tempest Therapeutics is trading at a lower price-to-earnings ratio than Aptevo Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aptevo Therapeutics N/A N/A -$25.97M -$51.83 N/A Tempest Therapeutics N/A N/A -$26.26M -$4.28 N/A

Is APVO or TPST more profitable?

Aptevo Therapeutics' return on equity of -201.49% beat Tempest Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aptevo Therapeutics N/A -201.49% -119.21% Tempest Therapeutics N/A -576.56% -134.99%

Do analysts recommend BIVI or APVO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioVie 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aptevo Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33

Which has stronger earnings & valuation, BIVI or APVO?

BioVie is trading at a lower price-to-earnings ratio than Aptevo Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BioVie N/A N/A -$22.07M -$3.15 N/A Aptevo Therapeutics N/A N/A -$25.97M -$51.83 N/A

Is BIVI or APVO more profitable?

BioVie's return on equity of -126.02% beat Aptevo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets BioVie N/A -126.02% -108.88% Aptevo Therapeutics N/A -201.49% -119.21%

Does the media favor BIVI or APVO?

In the previous week, BioVie had 7 more articles in the media than Aptevo Therapeutics. MarketBeat recorded 9 mentions for BioVie and 2 mentions for Aptevo Therapeutics. BioVie's average media sentiment score of 0.97 beat Aptevo Therapeutics' score of 0.93 indicating that BioVie is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioVie 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aptevo Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Aptevo Therapeutics (APVO) Competitors

$2.42 +0.06 (+2.32%)

As of 10:44 AM Eastern

Compare

APVO vs. PLUR, KTTA, NCEL, TPST, and BIVI

Should you buy Aptevo Therapeutics stock or one of its competitors? Aptevo Therapeutics's main competitors and comparable companies include Pluri (PLUR), Pasithea Therapeutics (KTTA), NLS Pharmaceutics (NCEL), Tempest Therapeutics (TPST), and BioVie (BIVI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Aptevo Therapeutics compare to Pluri?

Aptevo Therapeutics (NASDAQ:APVO) and Pluri (NASDAQ:PLUR) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aptevo Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Pluri	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

8.1% of Aptevo Therapeutics shares are owned by institutional investors. Comparatively, 16.6% of Pluri shares are owned by institutional investors. 0.5% of Aptevo Therapeutics shares are owned by company insiders. Comparatively, 43.2% of Pluri shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Pluri has higher revenue and earnings than Aptevo Therapeutics. Pluri is trading at a lower price-to-earnings ratio than Aptevo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aptevo Therapeutics	N/A	N/A	-$25.97M	-$51.83	N/A
Pluri	$1.08M	15.05	-$22.58M	-$4.53	N/A

Aptevo Therapeutics has a beta of 1.65, meaning that its stock price is 65% more volatile than the broader market. Comparatively, Pluri has a beta of 0.67, meaning that its stock price is 33% less volatile than the broader market.

In the previous week, Pluri had 2 more articles in the media than Aptevo Therapeutics. MarketBeat recorded 4 mentions for Pluri and 2 mentions for Aptevo Therapeutics. Aptevo Therapeutics' average media sentiment score of 0.93 beat Pluri's score of 0.81 indicating that Aptevo Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aptevo Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pluri	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aptevo Therapeutics has a net margin of 0.00% compared to Pluri's net margin of -2,162.08%. Pluri's return on equity of 0.00% beat Aptevo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aptevo Therapeutics	N/A	-201.49%	-119.21%
Pluri	-2,162.08%	N/A	-106.59%

Summary

Pluri beats Aptevo Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Aptevo Therapeutics compare to Pasithea Therapeutics?

Aptevo Therapeutics (NASDAQ:APVO) and Pasithea Therapeutics (NASDAQ:KTTA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, earnings, risk, valuation and dividends.

8.1% of Aptevo Therapeutics shares are held by institutional investors. Comparatively, 23.9% of Pasithea Therapeutics shares are held by institutional investors. 0.5% of Aptevo Therapeutics shares are held by insiders. Comparatively, 1.5% of Pasithea Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Pasithea Therapeutics is trading at a lower price-to-earnings ratio than Aptevo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aptevo Therapeutics	N/A	N/A	-$25.97M	-$51.83	N/A
Pasithea Therapeutics	N/A	N/A	-$20.43M	-$1.58	N/A

Pasithea Therapeutics has a consensus target price of $3.00, suggesting a potential upside of 436.67%. Given Pasithea Therapeutics' higher probable upside, analysts plainly believe Pasithea Therapeutics is more favorable than Aptevo Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aptevo Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Pasithea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Aptevo Therapeutics had 1 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 2 mentions for Aptevo Therapeutics and 1 mentions for Pasithea Therapeutics. Pasithea Therapeutics' average media sentiment score of 1.89 beat Aptevo Therapeutics' score of 0.93 indicating that Pasithea Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Aptevo Therapeutics	Positive
Pasithea Therapeutics	Very Positive

Aptevo Therapeutics has a beta of 1.65, indicating that its share price is 65% more volatile than the broader market. Comparatively, Pasithea Therapeutics has a beta of 0.29, indicating that its share price is 71% less volatile than the broader market.

Pasithea Therapeutics' return on equity of -49.49% beat Aptevo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aptevo Therapeutics	N/A	-201.49%	-119.21%
Pasithea Therapeutics	N/A	-49.49%	-46.81%

Summary

Pasithea Therapeutics beats Aptevo Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Aptevo Therapeutics compare to NLS Pharmaceutics?

Aptevo Therapeutics (NASDAQ:APVO) and NLS Pharmaceutics (NASDAQ:NCEL) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, media sentiment, profitability, dividends, risk and institutional ownership.

NLS Pharmaceutics' return on equity of 0.00% beat Aptevo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aptevo Therapeutics	N/A	-201.49%	-119.21%
NLS Pharmaceutics	N/A	N/A	N/A

8.1% of Aptevo Therapeutics shares are held by institutional investors. 0.5% of Aptevo Therapeutics shares are held by insiders. Comparatively, 16.4% of NLS Pharmaceutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

NLS Pharmaceutics has a consensus target price of $23.00, suggesting a potential upside of 578.47%. Given NLS Pharmaceutics' higher probable upside, analysts clearly believe NLS Pharmaceutics is more favorable than Aptevo Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aptevo Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
NLS Pharmaceutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aptevo Therapeutics	N/A	N/A	-$25.97M	-$51.83	N/A
NLS Pharmaceutics	N/A	N/A	-$8.30M	N/A	N/A

In the previous week, Aptevo Therapeutics and Aptevo Therapeutics both had 2 articles in the media. NLS Pharmaceutics' average media sentiment score of 0.94 beat Aptevo Therapeutics' score of 0.93 indicating that NLS Pharmaceutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aptevo Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NLS Pharmaceutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aptevo Therapeutics has a beta of 1.65, suggesting that its share price is 65% more volatile than the broader market. Comparatively, NLS Pharmaceutics has a beta of 0.94, suggesting that its share price is 6% less volatile than the broader market.

Summary

NLS Pharmaceutics beats Aptevo Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Aptevo Therapeutics compare to Tempest Therapeutics?

Aptevo Therapeutics (NASDAQ:APVO) and Tempest Therapeutics (NASDAQ:TPST) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk, valuation and media sentiment.

Aptevo Therapeutics has a beta of 1.65, suggesting that its stock price is 65% more volatile than the broader market. Comparatively, Tempest Therapeutics has a beta of -1.72, suggesting that its stock price is 272% less volatile than the broader market.

8.1% of Aptevo Therapeutics shares are held by institutional investors. Comparatively, 22.5% of Tempest Therapeutics shares are held by institutional investors. 0.5% of Aptevo Therapeutics shares are held by insiders. Comparatively, 36.2% of Tempest Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aptevo Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Tempest Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Aptevo Therapeutics' return on equity of -201.49% beat Tempest Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aptevo Therapeutics	N/A	-201.49%	-119.21%
Tempest Therapeutics	N/A	-576.56%	-134.99%

Tempest Therapeutics is trading at a lower price-to-earnings ratio than Aptevo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aptevo Therapeutics	N/A	N/A	-$25.97M	-$51.83	N/A
Tempest Therapeutics	N/A	N/A	-$26.26M	-$4.28	N/A

In the previous week, Aptevo Therapeutics had 1 more articles in the media than Tempest Therapeutics. MarketBeat recorded 2 mentions for Aptevo Therapeutics and 1 mentions for Tempest Therapeutics. Tempest Therapeutics' average media sentiment score of 1.89 beat Aptevo Therapeutics' score of 0.93 indicating that Tempest Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Aptevo Therapeutics	Positive
Tempest Therapeutics	Very Positive

Summary

Aptevo Therapeutics beats Tempest Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Aptevo Therapeutics compare to BioVie?

BioVie (NASDAQ:BIVI) and Aptevo Therapeutics (NASDAQ:APVO) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and institutional ownership.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioVie	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aptevo Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

BioVie's return on equity of -126.02% beat Aptevo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioVie	N/A	-126.02%	-108.88%
Aptevo Therapeutics	N/A	-201.49%	-119.21%

BioVie has a beta of 0.6, meaning that its share price is 40% less volatile than the broader market. Comparatively, Aptevo Therapeutics has a beta of 1.65, meaning that its share price is 65% more volatile than the broader market.

In the previous week, BioVie had 7 more articles in the media than Aptevo Therapeutics. MarketBeat recorded 9 mentions for BioVie and 2 mentions for Aptevo Therapeutics. BioVie's average media sentiment score of 0.97 beat Aptevo Therapeutics' score of 0.93 indicating that BioVie is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioVie	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aptevo Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

4.6% of BioVie shares are owned by institutional investors. Comparatively, 8.1% of Aptevo Therapeutics shares are owned by institutional investors. 0.9% of BioVie shares are owned by insiders. Comparatively, 0.5% of Aptevo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

BioVie is trading at a lower price-to-earnings ratio than Aptevo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioVie	N/A	N/A	-$22.07M	-$3.15	N/A
Aptevo Therapeutics	N/A	N/A	-$25.97M	-$51.83	N/A

Summary

BioVie beats Aptevo Therapeutics on 7 of the 12 factors compared between the two stocks.

Get Aptevo Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding APVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

APVO vs. The Competition

Export

Metric	Aptevo Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.39M	$3.90B	$7.10B	$12.83B
Dividend Yield	N/A	3.61%	2.54%	11.27%
P/E Ratio	-0.05	11.65	273.04	25.49
Price / Sales	N/A	1,396.25	686.65	123.03
Price / Cash	N/A	44.06	28.74	36.03
Price / Book	0.14	16.74	11.02	6.35
Net Income	-$25.97M	-$22.71M	$3.47B	$349.46M
7 Day Performance	0.62%	2.39%	1.03%	-0.11%
1 Month Performance	-41.00%	12.62%	8.03%	4.32%
1 Year Performance	-91.79%	53.90%	23.72%	14.79%

Aptevo Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
APVO Aptevo Therapeutics	1.4583 of 5 stars	$2.43 +2.3%	N/A	-92.0%	$4.39M	N/A	N/A	50
PLUR Pluri	0.9142 of 5 stars	$1.71 -3.4%	N/A	-71.0%	$18.45M	$1.34M	N/A	150	Gap Down
KTTA Pasithea Therapeutics	3.3629 of 5 stars	$0.54 +14.8%	$3.00 +456.2%	-30.7%	$18.02M	N/A	N/A	3	Positive News Gap Up
NCEL NLS Pharmaceutics	2.5814 of 5 stars	$3.26 -3.3%	$23.00 +605.5%	-85.0%	$17.44M	N/A	N/A	6	Gap Up
TPST Tempest Therapeutics	1.3386 of 5 stars	$1.04 +2.0%	N/A	-89.3%	$16.62M	N/A	N/A	20	Positive News Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:APVO) was last updated on 8/31/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aptevo Therapeutics (APVO) Competitors

APVO vs. PLUR, KTTA, NCEL, TPST, and BIVI

How does Aptevo Therapeutics compare to Pluri?

Summary

How does Aptevo Therapeutics compare to Pasithea Therapeutics?

Summary

How does Aptevo Therapeutics compare to NLS Pharmaceutics?

Summary

How does Aptevo Therapeutics compare to Tempest Therapeutics?

Summary

How does Aptevo Therapeutics compare to BioVie?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APVO vs. The Competition

Aptevo Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aptevo Therapeutics (APVO) Competitors

APVO vs. PLUR, KTTA, NCEL, TPST, and BIVI

How does Aptevo Therapeutics compare to Pluri?

Do analysts rate APVO or PLUR?

Do insiders & institutionals believe in APVO or PLUR?

Which has higher valuation & earnings, APVO or PLUR?

Which has more volatility & risk, APVO or PLUR?

Does the media prefer APVO or PLUR?

Is APVO or PLUR more profitable?

Summary

How does Aptevo Therapeutics compare to Pasithea Therapeutics?

Do institutionals and insiders have more ownership in APVO or KTTA?

Which has stronger valuation and earnings, APVO or KTTA?

Do analysts prefer APVO or KTTA?

Does the media favor APVO or KTTA?

Which has more volatility and risk, APVO or KTTA?

Is APVO or KTTA more profitable?

Summary

How does Aptevo Therapeutics compare to NLS Pharmaceutics?

Is APVO or NCEL more profitable?

Do insiders & institutionals hold more shares of APVO or NCEL?

Do analysts rate APVO or NCEL?

Which has preferable valuation and earnings, APVO or NCEL?

Does the media refer more to APVO or NCEL?

Which has more risk & volatility, APVO or NCEL?

Summary

How does Aptevo Therapeutics compare to Tempest Therapeutics?

Which has more risk and volatility, APVO or TPST?

Do insiders and institutionals believe in APVO or TPST?

Do analysts rate APVO or TPST?

Is APVO or TPST more profitable?

Which has better earnings and valuation, APVO or TPST?

Does the media prefer APVO or TPST?

Summary

How does Aptevo Therapeutics compare to BioVie?

Do analysts recommend BIVI or APVO?

Is BIVI or APVO more profitable?

Which has more volatility and risk, BIVI or APVO?

Does the media favor BIVI or APVO?

Do insiders & institutionals hold more shares of BIVI or APVO?

Which has stronger earnings & valuation, BIVI or APVO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APVO vs. The Competition

Aptevo Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools